A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).

Authors

Ferdinandos Skoulidis

The University of Texas MD Anderson Cancer Center, Houston, TX

Ferdinandos Skoulidis , Joel W. Neal , Wallace L. Akerley , Paul K. Paik , Thales Papagiannakopoulos , Karen L. Reckamp , Jonathan W. Riess , Yonchu Jenkins , Sacha Holland , Francesco Parlati , Yijing Shen , Sam H. Whiting , Naiyer A. Rizvi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.

First Author: Marina Chiara Garassino

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).

First Author: Myung-Ju Ahn

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

STAR-121: A phase 3, randomized study of domvanalimab (DOM) and zimberelimab (ZIM) in combination with chemotherapy vs pembrolizumab (pembro) and chemotherapy in patients with untreated metastatic non-small cell lung cancer (mNSCLC) with no actionable gene alterations.

First Author: Delvys Rodriguez-Abreu

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.

First Author: Charu Aggarwal